Last updated 16 days ago
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
160 patients around the world
Available in Argentina
Merck Sharp & Dohme LLC
5Research sites
160Patients around the world
This study is for people with
Pulmonary hypertension
Pulmonary arterial hypertension
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Has documented diagnostic Right Heart Catheterization, with the diagnosis of World Health Organization (WHO) Pulmonary Atrial Hypertension (PAH) Group 1 in any of the following subtypes: Idiopathic PAH, Heritable PAH, Drug/toxin-induced PAH, PAH associated with connective tissue disease, PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair.Has symptomatic PAH classified as WHO Functional Class II or III.
- Has a weight of <35 kg.Has a diagnosis of PH WHO Groups 2, 3, 4, or 5.Has a diagnosis of the following PAH Group 1 subtypes: HIV-associated PAH, PAH associated with portal hypertension, Exclusion in PAH Group 1 should also include schistosomiasis-associated PAH, pulmonary veno occlusive disease and pulmonary capillary hemangiomatosis.Has uncontrolled systemic hypertension.Has a history of pneumonectomy.Has a history of known pericardial constriction.Has a history of restrictive cardiomyopathy.Has history of atrial septostomy (within 180 days prior to study start).Has personal or family history of long QT syndrome.Has history of coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass, graft surgery, or cardiac anginal chest pain) (within 6 months prior to study start).Has a cerebrovascular accident (within 3 months prior to study start).Has significant (>2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease.Has untreated more than mild obstructive sleep apnea.Has known malignancy that is progressing or has required active treatment within the past 5 years.Has recently started (within 12 months prior to study start) or has plans to start weight loss medication or enter a weight loss program during the study period.Has a previous (within 3 years) or planned (during the study) obesity treatment with surgery or a weight-loss device.
Sites
Hospital Británico de Buenos Aires - CABA
Recruiting
Instituto de Cardiología Juana Francisca Cabral - Corrientes
Recruiting
Hospital Dr. José María Cullen
Recruiting
Centro Médico Capital
Recruiting
Instituto Médico Río Cuarto
Recruiting
StudyLIGHTRAY
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Pulmonary arterial hypertension
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06664801
